Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness

Annals of Pharmacotherapy

Volumn 43, Issue 5, 2009, Pages 862-867

  Purvis, Tara L ^a   Mambourg, Scott E ^b   Balvanz, Tracie M ^b   Magallon, Heather E ^b   Pham, Richard H ^b  

^a Western Missouri Mental Health Center   (United States)

^b Veterans Affairs Sierra Nevada Health Care System   (United States)

Author keywords

Chantix; Effectiveness; Safety; Smoking cessation; Tobacco; Varenicline

Indexed keywords

VARENICLINE;

ADULT; AGED; AGGRESSION; AGITATION; ANAMNESIS; ARTICLE; BEHAVIOR DISORDER; CLINICAL FEATURE; CONSTIPATION; CONTROLLED STUDY; DREAMING; DRIVING ABILITY; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MOOD DISORDER; NAUSEA; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; SUICIDAL IDEATION; TELECONSULTATION; TOBACCO DEPENDENCE; TREATMENT FAILURE; VETERAN;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BENZAZEPINES; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NICOTINIC AGONISTS; QUINOXALINES; RETROSPECTIVE STUDIES; SEX FACTORS; SMOKING CESSATION; TOBACCO USE DISORDER; VETERANS;

EID: 65749117519     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L661     Document Type: Article

References (26)

1. 2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 2006;34:121-130
2. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007;52:985-994
3. 2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 2006;296:47-55.
4. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006;296:56-63.
5. Oncken CO, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166:1571-1577
6. 2 nicotinic receptor partial agonist. Arch Intern Med 2006; 166:1561-1568
7. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation. JAMA 2006;296:64-71.
8. Food and Drug Administration. Varenicline (marketed as Chantix) information. www.fda.gov/cder/drug/infopage/varenicline/htm (accessed 2008 Jun 7).
9. Institute for Safe Medication Practices. Strong safety signal seen for new varenicline risks. www.ismp.org/docs/chantixreport.asp (accessed 2008 May 25).
10. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA 2000;284:2606-2610
11. Black DW, Zimmerman M, Coryell WH. Cigarette smoking and psychiatric disorder in a community sample. Ann Clin Psychiatry 1999;11:129-136 (Pubitemid 29420228)
12. Gelenberg AJ, de Leon J, Evins AE, Parks JJ, Rigotti NA. Smoking in patients with psychiatric disorders. J Clin Psychiatry 2007;68:1404-1410 (Pubitemid 47524521)
13. Glassman AH. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 1993;150:546-553 (Pubitemid 23109920)
14. United States Department of Veterans Affairs. Varenicline preliminary criteria for prescribing June 2008. www.pbm.va.gov/guidelines/Varenicline PreliminaryPrescribingGuidance.doc (accessed 2008 Oct 27).
15. Product information. Chantix (varenicline). New York: Pfizer, January 2008.
16. Glassman AH, Covey LS, Dalack GW, et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 1993;54:670-679
17. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. JAMA 1990;264:1546-1549
18. Covey LS, Glassman AH, Stetner F. Major depression following smoking cessation. Am J Psychiatry 1997;154:263-265 (Pubitemid 27053736)
19. Tsoh JY, Humfleet GL, Munoz RF, Reus VI, Hartz DT, Hall SM. Development of major depression after treatment for smoking cessation. Am J Psychiatry 2000;57:368-374 (Pubitemid 30145921)
20. Niaura R, Britt DM, Shadel WG, Goldstein M, Abrams D, Brown R. Symptoms of depression and survival experience among three samples of smokers trying to quit. Psychol Addict Behav 2001;15:13-17 (Pubitemid 32194935)
21. Thorsteinsson HS, Gillin JC, Patten CA, et al. The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression. Neuropsychopharmacology 2001;24:350-358
22. Addington J, el Guebaly N, Campbell W, Hodgins DC, Addington D. Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry 1998;155:974-976
23. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000;157:1835-1842.
24. Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 1999;21:195-202. (Pubitemid 29304580)
25. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002; 52:53-61.
26. Hughes JR, Frances RJ. How to help psychiatric patients stop smoking. Psychiatr Serv 1995;46:435-436